Drug discovery in advanced prostate cancer: translating biology into therapy.
MetadataShow full item record
Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs.
Molecular Targeted Therapy
Translational Medical Research
Prostatic Neoplasms, Castration-Resistant
Computational Biology and Chemogenomics
Medicine Drug Development Unit (de Bono)
Prostate Cancer Targeted Therapy Group
License start date
Nature reviews. Drug discovery, 2016, 15 (10), pp. 699 - 718